A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD).

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2014

At a glance

  • Drugs Vilazodone (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors PGxHealth
  • Most Recent Events

    • 09 Oct 2013 Pooled post-hoc analysis assessing sustained response presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 09 Oct 2013 Pooled post-hoc analysis assessing the effects of treatment on anxiety outcomes presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
    • 23 Nov 2011 Results published in the Current Medical Research and Opinion.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top